Eculizumab for pregnancy-related atypical hemolytic uremic syndrome

Korotchaeva Y. , Kozlovskaya N. , Shifman E. , Kudlay D. , Moiseev S.

NEPHROLOGY DIALYSIS TRANSPLANTATION

Oxford University Press

10

Английский

1731-1733

Опубликовано

Внешняя ссылка

10.1093/NDT/GFAE068

39

2024

• ¹ Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russian Federation
• ² Nephrology Center for Pregnant Women with Kidney Disease, Eramishantsev City Clinical Hospital, Moscow, Russian Federation
• ³ Department of Internal Medicine, Peoples’ Friendship University of Russia, Moscow, Russian Federation
• ⁴ Department of Anesthesiology and Intensive Care, Vladimirsky Moscow Regional Scientific Research Institute, Moscow, Russian Federation

Adult; Antibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Complement Inactivating Agents; Female; Humans; Pregnancy; Pregnancy Complications; cephalosporin; creatinine; cyclophosphamide; eculizumab; hemoglobin; lactate dehydrogenase; monoclonal antibody; quinolone derivative; complement inhibitor; eculizumab; monoclonal antibody; acute heart failure; acute kidney failure; adult; adult respiratory distress syndrome; all cause mortality; anuria; Article; atypical hemolytic uraemic syndrome; bleeding; blood brain barrier; cerebrovascular accident; chronic kidney failure; coma; complement inhibition; controlled study; dialysis; end stage renal disease; endothelium lesion; female; follow up; heart infarction; hemodialysis; human; liver injury; major clinical study; microangiopathic hemolytic anemia; microangiopathy; microvascular thrombosis; morbidity; mortality; platelet count; preeclampsia; pregnancy; renal replacement therapy; seizure; systemic thrombotic microangiopathy; tertiary care center; thrombocytopenia; thrombotic microangiopathy; thrombotic thrombocytopenic purpura; vascular microthrombosis; atypical hemolytic uraemic syndrome; case report; drug therapy; pregnancy; pregnancy complication